Immuneering Corp (IMRX) stock

IMRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/30

$3.71+0.04 (+1.09%)

Close on Nov 13, 2026Market cap $240.27MP/E –Yield –

Immuneering EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Immuneering has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?